Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers

References

• Gawatz M. Blood platelets. Stuttgart 2001, Thieme
   Google Scholar
• Bartsch P. Platelet activation with exercise and risk of cardiac events. Lancet 1999; 354: 1474–1478
   Web of Science ®Google Scholar
• Wang JS, Jen CJ, Chen H-I. Effects of exercise training and deconditioning on platelet function in men. Arterioscler Thromb Vasc Biol 1995; 15: 1668–1674
   PubMed Web of Science ®Google Scholar
• Wang JS, Cheng L-J. Effect of strenuous, acute exercise on α2-adrenergic agonist-potentiaged platelet activation. Arterioscler Thromb Vasc Biol 1999; 19: 1559–1565
   PubMed Web of Science ®Google Scholar
• Li N, Wallén NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999; 100: 1374–1379
   PubMed Web of Science ®Google Scholar
• Broadley AJM, Gapper P, Schmitt M, Frenneaux MP. Supine rest reduces platelet activation and aggregation. Platelets 2003; 14: 3–7
   PubMed Web of Science ®Google Scholar
• El Sayed MS, Ali N, El-Sayed Ali Z. Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. Sports Med 1996; 22: 282–289
   PubMed Web of Science ®Google Scholar
• Willich SN, Lewis M, Löwel H, Arntz H-R, Schubert F, Schröder R. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med 1993; 329: 1684–1690
   PubMed Web of Science ®Google Scholar
• Dimsdale J, Moss J. Plasma catecholamines in stress and exercise. JAMA 1980; 243: 240–242
   Web of Science ®Google Scholar
• Mazzeo RS. Catecholamine responses to acute and chronic exercise. Med Sci Sports Exerc 1991; 23: 433–453
   Web of Science ®Google Scholar
• El-Sayed MS. Exercise and training effects on platelets in health and disease. Platelets 2002; 13: 261–266
   PubMed Web of Science ®Google Scholar
• Broadley AJM, Schmitt M, Frenneaux MP. Inhibition of platelet aggregation by nitric oxide donors improves with rest. Platelets 2003; 14: 347–349
   PubMed Web of Science ®Google Scholar
• Hilberg T, Eichler E, Gläser D, Prasa D, Stürzebecher J, Gabriel HHW. Blood coagulation and fibrinolysis before and after exhaustive exercise in patients with IDDM. Thromb Haemost 2003; 90: 1065–1073
   PubMed Web of Science ®Google Scholar
• Wang JS, Jen CJ, Chen H-I. Effects of short-term exercise on female platelet function during different phases of the menstrual cycle. Arterioscler Thromb Vasc Biol 1997; 17: 1682–1686
   PubMed Web of Science ®Google Scholar
• Smith WL, Garavito RM, DeWitt RM. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157–33160
   PubMed Web of Science ®Google Scholar
• Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38: 97–120
   PubMed Web of Science ®Google Scholar
• FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879–890
   PubMed Web of Science ®Google Scholar
• McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, GitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272–277
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735–741
   PubMed Web of Science ®Google Scholar
• Grosser T, Fries S, FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4–15
   PubMed Web of Science ®Google Scholar
• Hermann A, Rauch BH, Braun M, Schrör K, Weber A-A. Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74–82
   PubMed Web of Science ®Google Scholar
• Weber A-A, Schrör K. Differential inhibition of adenosine diphosphate versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics. Blood 2001; 98: 1619–1621
   PubMed Web of Science ®Google Scholar
• Weber A-A, Liesener S, Schanz A, Hohlfeld T, Schrör K. Habitual smoking causes an abnormality in platelet thromboxane A2 metabolism and results in an altered susceptibility to aspirin effects. Platelets 2000; 11: 177–182
   PubMed Web of Science ®Google Scholar
• Weber A-A, Przytulski B, Schanz A, Hohlfeld T, Schrör K. Towards a definition of aspirin resistance: A typological approach. Platelets 2002; 13: 37–40
   PubMed Web of Science ®Google Scholar
• Weber A-A, Hohlfeld T, Schrör K. cAMP is an important messenger for ADP-induced platelet aggregation. Platelets 1999; 10: 238–241
   PubMed Web of Science ®Google Scholar
• Weber A-A, Reimann S, Schrör K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 1999; 126: 415–420
   PubMed Web of Science ®Google Scholar
• Lindemann S, Klingel B, Fisch A, Meyer J, Darius H. Increased platelet sensitivity towards platelet inhibitors during physical exercise in patients with coronary artery disease. Thromb Res 1999; 93: 51–59
   PubMed Web of Science ®Google Scholar
• Hilberg T, Schmidt V, Gläser D, Schammne D, Lösche W, Gabriel HHW. Platelet activity, sensitivity to agonist, and platelet-leukocyte conjugate formation after long-term exercise. Platelets 2002; 13: 273–277
   PubMed Web of Science ®Google Scholar
• Hilberg T, Gläser D, Schmidt V, Lösche W, Franke G, Schneider K, Gabriel HHW. Short-term exercise and platelet activity, sensitivity to agonists, and platelet-leukocyte conjugate formation. Platelets 2003; 14: 67–74
   PubMed Web of Science ®Google Scholar
• Hilberg T, Eichler E, Gläser D, Schmidt V, Gabriel HHW. Platelet activity, reactivity and platelet-leukocyte conjugate formation before and after exhaustive or moderate exercise in patients with IDDM. Platelets 2004; 15: 101–109
   PubMed Web of Science ®Google Scholar
• Laustiola K, Seppälä E, Nikkari T, Vapaatalo H. Exercise-induced increase in plasma arachidonic acid and thromboxane B2 in healthy men: Effect of β-adrenergic blockade. J Cardiovasc Pharmacol 1984; 6: 449–454
   PubMed Web of Science ®Google Scholar
• Lemne C, Vesterqvist O, Egberg N, Green K, Jogestrand T, de Faire U. Platelet activation and prostacyclin release in essential hypertension. Prostaglandins 1992; 44: 219–235
   PubMed Web of Science ®Google Scholar
• Todd MK, Goldfarb AH, Burleson C. Comparison of methods for evaluating exercise-induced changes in thromboxane B2 and -thromboglobulin. Med Sci Sports Exercise 1997; 29: 700–704
   PubMed Web of Science ®Google Scholar
• Belton O, Byrne D, Kearney D, Leahey A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840–845
   PubMed Web of Science ®Google Scholar
• FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065–1068
   PubMed Web of Science ®Google Scholar
• Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983–989
   PubMed Web of Science ®Google Scholar
• Glenn JR, Heptinstall S. Evidence that adenosine diphosphate can activate adenylate cyclase via conversion to adenosine in platelet-rich plasma containing magnesium. Thromb Haemost 1998; 80: 321–325
   PubMed Web of Science ®Google Scholar
• Hardy E, Glenn J, Heptinstall S, Rubin PC, Horn EH. Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP. Thromb Haemost 1995; 74: 1132–1137
   PubMed Web of Science ®Google Scholar
• Pistono M, Bergerone S, Carrieri L, Paglia I, Stefano D, Capizzi A, Ferri M, Pescarmona G, Bosia A, Trevi G. Platelet cyclic GMP levels in unstable angina and myocardial infarction. Platelets 2003; 13: 307–311
   Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–1528
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–1255
   Google Scholar
• Wallberg-Jonsson S, Cederfelt M, Rantapaa Dahlquist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: An 8 year follow up study. J Rheumatol 2000; 27: 717–5
   Google Scholar
• DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 2002; 89: 33D–38
   Web of Science ®Google Scholar